



April 20, 2017

Immune Design Announces Presentations at the 2017 ASCO Annual Meeting

SEATTLE and SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that new and updated data from two ongoing clinical trials of CMB305 and G100, as well as translational data examining the association of immunological response with improved survival in CMB305 and LV305 patients, will be presented in an oral and two posters presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 - 6, 2017 in Chicago. The ASCO presentation details are as follows:

ORAL PRESENTATION

Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS)

Abstract # 11006

Session Title: Sarcoma

Date: Friday, June 2, 2017

Time: 3 p.m. — 6 p.m. CT (oral session)

Location: S100bc

Presenter: Neeta Somaiah, M.D., Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center

POSTER PRESENTATIONS

The Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients

Abstract # 3090

Session Title: Developmental Therapeutics—Immunotherapy

Date: Monday, June 5, 2017

Time: 8 a.m. — 11:30 a.m. CT (poster session)

Location: Hall A

Presenter: Seth M. Pollack, M.D., Fred Hutchinson Cancer Research Center

Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma

Abstract # 7537

Session Title: Hematologic Malignancies — Lymphoma and Chronic Lymphocytic Leukemia

Date: Monday, June 5, 2017

Time: 8 a.m. — 11:30 a.m. CT (poster session)

Location: Hall A

Presenter: Christopher Flowers, M.D., Department of Hematology and Medical Oncology, Emory University School of Medicine

Additional data than those included in the abstracts may be included in the presentations.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immunology clinical programs, are products of its two synergistic discovery platforms, ZVex and GLAAS, the fundamental technologies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Media Contact

Julie Rathbun

Rathbun Communications

julie@rathbuncomm.com

206-769-9219

Investor Contact

Shari Annes

Annes Associates

sannes@annesassociates.com

650-888-0902